Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−32.0 JPY
17.05 B JPY
1.60 T JPY
1.71 B
About ASTELLAS PHARMA
Sector
CEO
Naoki Okamura
Headquarters
Tokyo
Website
Founded
1923
ISIN
JP3942400007
FIGI
BBG000BCLF85
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products: XTANDI, PADCEV, XOSPATA, VYLOY, VEOZAH, IZERVAY, EVRENZO, BETANIS and PROGRAF. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 4503 is 1,465.5 JPY — it has increased by 0.83% in the past 24 hours. Watch ASTELLAS PHARMA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSE exchange ASTELLAS PHARMA stocks are traded under the ticker 4503.
4503 stock has fallen by −2.46% compared to the previous week, the month change is a −1.81% fall, over the last year ASTELLAS PHARMA has showed a −12.30% decrease.
We've gathered analysts' opinions on ASTELLAS PHARMA future price: according to them, 4503 price has a max estimate of 2,400.00 JPY and a min estimate of 1,400.00 JPY. Watch 4503 chart and read a more detailed ASTELLAS PHARMA stock forecast: see what analysts think of ASTELLAS PHARMA and suggest that you do with its stocks.
4503 reached its all-time high on May 25, 2023 with the price of 2,360.5 JPY, and its all-time low was 512.0 JPY and was reached on Sep 25, 2002. View more price dynamics on 4503 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
4503 stock is 1.41% volatile and has beta coefficient of 0.34. Track ASTELLAS PHARMA stock price on the chart and check out the list of the most volatile stocks — is ASTELLAS PHARMA there?
Today ASTELLAS PHARMA has the market capitalization of 2.64 T, it has decreased by −2.15% over the last week.
Yes, you can track ASTELLAS PHARMA financials in yearly and quarterly reports right on TradingView.
ASTELLAS PHARMA is going to release the next earnings report on Apr 24, 2025. Keep track of upcoming events with our Earnings Calendar.
4503 earnings for the last quarter are −54.55 JPY per share, whereas the estimation was 7.35 JPY resulting in a −842.18% surprise. The estimated earnings for the next quarter are 20.53 JPY per share. See more details about ASTELLAS PHARMA earnings.
ASTELLAS PHARMA revenue for the last quarter amounts to 517.41 B JPY, despite the estimated figure of 447.53 B JPY. In the next quarter, revenue is expected to reach 427.01 B JPY.
4503 net income for the last quarter is −97.66 B JPY, while the quarter before that showed 35.91 B JPY of net income which accounts for −371.97% change. Track more ASTELLAS PHARMA financial stats to get the full picture.
ASTELLAS PHARMA dividend yield was 4.26% in 2023, and payout ratio reached 736.46%. The year before the numbers were 3.19% and 110.62% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Feb 21, 2025, the company has 14.75 K employees. See our rating of the largest employees — is ASTELLAS PHARMA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ASTELLAS PHARMA EBITDA is 431.16 B JPY, and current EBITDA margin is 20.95%. See more stats in ASTELLAS PHARMA financial statements.
Like other stocks, 4503 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ASTELLAS PHARMA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ASTELLAS PHARMA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ASTELLAS PHARMA stock shows the sell signal. See more of ASTELLAS PHARMA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.